BACE Trial Substudy 1 - PROactive Substudy (PROactive)

BACE Trial - Physical Activity as a Crucial Patient Reported Outcome in COPD

A first sub-analysis of the BACE trial will address physical activity levels in a subgroup of the intervention study with portable validated activity monitors.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: Placebo; Drug: Azithromycin; Device: Dynaport®

Detailed Description

Physical activity is strongly reduced with exacerbations and failure to increase physical activity is associated with relapse. In addition, physical inactivity is known to be associated with cardiovascular and metabolic morbidity and is one of the strongest predictors of mortality in COPD. Apart from potential direct effects of the intervention on treatment failure and symptoms, positive effects on physical activity may offer considerable benefits in the long run.

Randomized patients that are willing to participate in the sub-study will be monitored for activity by validated and easy-to-wear portable devices (Dynaport®). This activity monitor was recently thoroughly validated for use in COPD by the Pro-Active consortium and will be used at the baseline, 3 months and 9 months visit. We hypothesize that with a positive medical intervention, differences in recovery of physical activity will be appreciated.

Patients will follow the standard protocol but will also wear the activity monitor for 7 days post discharge from hospital (at investigator discretion), at day 90 (end of treatment) and at day 270 (end of follow-up). This device is not only registering physical activity for 7 days but is also coupled to a standardized and patient-validated questionnaire on physical activities which needs to be filled out at day 8 to cover a recall period of 7 (monitored) days.

Patient will have to give informed consent for the additional measures that are related to the activity sub-study. However, individual patients can still opt out for these tests (sub-study) and only participate in the medical intervention study (main study).

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Brussels Hoofdstedelijk Gewest
    • Brussel, Brussels Hoofdstedelijk Gewest, Belgium, 1000
      • St. Pieterziekenhuis
  • Vlaanderen
    • Antwerpen, Vlaanderen, Belgium, 2020
      • ZNA Middelheim
    • Bonheiden, Vlaanderen, Belgium, 2820
      • Imelda Ziekenhuis
    • Gent, Vlaanderen, Belgium, 9000
      • UZ Gent
    • Hasselt, Vlaanderen, Belgium, 3500
      • Jessa Ziekenhuis
    • Leuven, Vlaanderen, Belgium, 3000
      • UZ Gasthuisberg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)
• Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years, etc.)
• Current hospitalization for potential infectious AECOPD treated with standard therapy
• History of at least one exacerbation during the last year (prior to the current hospital admission) for which systemic steroids and/or antibiotics were taken
• ECG at admission

Exclusion Criteria:

• Mechanical or non-invasive ventilation at moment of randomization (D1)
• Long QT interval on ECG (QTc > 450msec for males or > 470msec for females)
• History of life-threatening arrhythmias
• Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug
• Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission
• Drugs with high risk for long QT interval and torsade de pointes (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)
• Documented uncorrected severe hypokalemia (K+ < 3.0 mmol/L) or hypomagnesemia (Mg2+ < 0.5 mmol/L)
• Chronic systemic steroids (> 4 mg methylprednisolone /day for ≥ 2 months)
• Actual use of macrolides for at least 2 weeks
• Allergy to macrolides
• Active cancer treatment
• Life expectancy < 3 months
• Pregnant or breast-feeding subjects. Woman of childbearing potential must have a pregnancy test performed and a negative result must be documented before start of treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Azithromycin; N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity	Drug: Azithromycin; From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days; Other Names: Azitromcyine CF; ATC code: J01FA10; Device: Dynaport®; Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months; Other Names: Activity monitor
Placebo Comparator: Placebo; N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity	Drug: Placebo; Other Names: Inactive substance; Device: Dynaport®; Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months; Other Names: Activity monitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in Physical Activity (total amount of steps) registered by the Dynaport® during 7 days between discharge from hospital (0 months) and 3 months after randomisation	Physical activity will be quantified as Total amount of steps	At discharge from hospital (0 months) and 3 months after start study drug intake

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Key secondary endpoint: Different change in physical activity (total amount of steps) at 3 months between placebo and azithromycin arm	Difference between placebo and azithromycin arm in physical activity changes registered by the Dynaport® during 7 days at discharge from hospital (0 months) and at 3 months	0 and 3 months
Different change in physical activity (total amount of steps) at 9 months between placebo and azithromycin arm	Difference between placebo and azithromycin arm in physical activity changes registered by the Dynaport® during 7 days at discharge from hospital (0 months) and at 9 months	at baseline and 9 months
Difference in Physical Activity (TSMVA) registered by the Dynaport® during 7 days between discharge from hospital (0 months) and 9 months, or between 3 months and 9 months after randomisation	Physical activity will be specified for: Total amount of steps; Total time spent in moderate to intense physical activity; Sedentary Time (Lying-Sitting) and Time Active (Standing-Locomotion-Shuffeling)	baseline, 3 and 9 months
Difference in Physical Activity (TSMVA) registered by the Dynaport® during 7 days between discharge from hospital (0 months) and 3 months after randomisation	Physical activity will be specified for: Total time spent in moderate to intense physical activity; Sedentary Time (Lying-Sitting) and Time Active (Standing-Locomotion-Shuffeling)	At discharge from hospital (0 months) and 3 months after start study drug intake

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory endpoint: sensitivity analysis of primary and secondary endpoints in subgroups	Male vs female; Smoker vs ex-smoker (stopped smoking > 6 months); GOLD A, B vs GOLD C vs GOLD D; Former GOLD I, II vs III vs IV; High CRP (> 50 mg/dL) vs low CRP (< 50 mg/dL); Age < 60 years vs age 60 - 70 years vs age > 70 years; Anthonissen I vs Anthonissen II vs Anthonissen III at admission; ICS use vs no ICS use	at 0, 3 and 9 months

Collaborators and Investigators

• Sponsor: Wim Janssens
• Collaborators: Pro-Active Medical Pty Ltd
• Investigators: Principal Investigator: Wim Janssens, MD PhD, KU Leuven

Study record dates

Study Major Dates

• Study Start: September 1, 2014
• Primary Completion (Actual): April 1, 2018
• Study Completion (Actual): April 1, 2020

Study Registration Dates

• First Submitted: July 22, 2014
• First Submitted That Met QC Criteria: July 30, 2014
• First Posted (Estimate): July 31, 2014

Study Record Updates

• Last Update Posted (Actual): April 8, 2020
• Last Update Submitted That Met QC Criteria: April 7, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Physical Activity; AECOPD; Randomized Controlled Trial; Azithromycin; Chronic Obstructive Pulmonary Disease; Acute exacerbation; Placebo; Macrolides; Hospitalization; Activity Monitor; PRO-Active
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Anti-Infective Agents; Anti-Bacterial Agents; Azithromycin
• Other Study ID Numbers: s55829 - PROactive Substudy

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO